Biodegradable Nanoparticle for Cornea Drug Delivery: Focus Review

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Dec 23

PMID 33353013

Citations 16

Authors

Mohammadmahdi Mobaraki

Madjid Soltani

Samaneh Zare Harofte

Elham L Zoudani

Roshanak Daliri

Mohamadreza Aghamirsalim

Kaamran Raahemifar

Affiliations

Soon will be listed here.

Abstract

During recent decades, researchers all around the world have focused on the characteristic pros and cons of the different drug delivery systems for cornea tissue change for sense organs. The delivery of various drugs for cornea tissue is one of the most attractive and challenging activities for researchers in biomaterials, pharmacology, and ophthalmology. This method is so important for cornea wound healing because of the controllable release rate and enhancement in drug bioavailability. It should be noted that the delivery of various kinds of drugs into the different parts of the eye, especially the cornea, is so difficult because of the unique anatomy and various barriers in the eye. Nanoparticles are investigated to improve drug delivery systems for corneal disease. Biodegradable nanocarriers for repeated corneal drug delivery is one of the most attractive and challenging methods for corneal drug delivery because they have shown acceptable ability for this purpose. On the other hand, by using these kinds of nanoparticles, a drug could reside in various part of the cornea for longer. In this review, we summarized all approaches for corneal drug delivery with emphasis on the biodegradable nanoparticles, such as liposomes, dendrimers, polymeric nanoparticles, niosomes, microemulsions, nanosuspensions, and hydrogels. Moreover, we discuss the anatomy of the cornea at first and gene therapy at the end.

Citing Articles

Drug delivery strategies to improve the treatment of corneal disorders.

Tafti M, Fayyaz Z, Aghamollaei H, Jadidi K, Faghihi S Heliyon. 2025; 11(2):e41881.

PMID: 39897787 PMC: 11783021. DOI: 10.1016/j.heliyon.2025.e41881.

Biomedical Application of MSCs in Corneal Regeneration and Repair.

De Miguel M, Cadenas-Martin M, Stokking M, Martin-Gonzalez A Int J Mol Sci. 2025; 26(2).

PMID: 39859409 PMC: 11766311. DOI: 10.3390/ijms26020695.

Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology.

Qi Q, Su D, Zhuang S, Yao S, Heindl L, Fan X Adv Sci (Weinh). 2025; 12(6):e2407340.

PMID: 39755928 PMC: 11809354. DOI: 10.1002/advs.202407340.

The Emerging Role of Silk Fibroin for the Development of Novel Drug Delivery Systems.

Pollini M, Paladini F Biomimetics (Basel). 2024; 9(5).

PMID: 38786505 PMC: 11117513. DOI: 10.3390/biomimetics9050295.

Nanoparticle-Mediated Cell Delivery: Advancements in Corneal Endothelial Regeneration.

Mallareddy V, Daigavane S Cureus. 2024; 16(3):e56958.

PMID: 38665717 PMC: 11044897. DOI: 10.7759/cureus.56958.

References

Lai S, Wei Y, Wu Q, Zhou K, Liu T, Zhang Y . Liposomes for effective drug delivery to the ocular posterior chamber. J Nanobiotechnology. 2019; 17(1):64. PMC: 6515668. DOI: 10.1186/s12951-019-0498-7. View

Sharma A, Rodier J, Tandon A, Klibanov A, Mohan R . Attenuation of corneal myofibroblast development through nanoparticle-mediated soluble transforming growth factor-β type II receptor (sTGFβRII) gene transfer. Mol Vis. 2012; 18:2598-607. PMC: 3482172. View

Soltani M, Chen P . Numerical modeling of fluid flow in solid tumors. PLoS One. 2011; 6(6):e20344. PMC: 3108959. DOI: 10.1371/journal.pone.0020344. View

Soriano-Romani L, Alvarez-Trabado J, Lopez-Garcia A, Molina-Martinez I, Herrero-Vanrell R, Diebold Y . Improved in vitro corneal delivery of a thrombospondin-1-derived peptide using a liposomal formulation. Exp Eye Res. 2017; 167:118-121. DOI: 10.1016/j.exer.2017.12.002. View

Ali M, Horikawa S, Venkatesh S, Saha J, Hong J, Byrne M . Zero-order therapeutic release from imprinted hydrogel contact lenses within in vitro physiological ocular tear flow. J Control Release. 2007; 124(3):154-62. DOI: 10.1016/j.jconrel.2007.09.006. View

Ustundag Okur N, Caglar E, Siafaka P . Novel Ocular Drug Delivery Systems: An Update on Microemulsions. J Ocul Pharmacol Ther. 2020; 36(6):342-354. DOI: 10.1089/jop.2019.0135. View

Hoffman A . Hydrogels for biomedical applications. Adv Drug Deliv Rev. 2002; 54(1):3-12. DOI: 10.1016/s0169-409x(01)00239-3. View

Oktay A, Ilbasmis-Tamer S, Celebi N . The effect of critical process parameters of the high pressure homogenization technique on the critical quality attributes of flurbiprofen nanosuspensions. Pharm Dev Technol. 2019; 24(10):1278-1286. DOI: 10.1080/10837450.2019.1667384. View

Torrecilla J, Gomez-Aguado I, Vicente-Pascual M, Del Pozo-Rodriguez A, Solinis M, Rodriguez-Gascon A . MMP-9 Downregulation with Lipid Nanoparticles for Inhibiting Corneal Neovascularization by Gene Silencing. Nanomaterials (Basel). 2019; 9(4). PMC: 6523231. DOI: 10.3390/nano9040631. View

10.

Khalil M, Hashmi U, Riaz R, Abbas S . Chitosan coated liposomes (CCL) containing triamcinolone acetonide for sustained delivery: A potential topical treatment for posterior segment diseases. Int J Biol Macromol. 2019; 143:483-491. DOI: 10.1016/j.ijbiomac.2019.10.256. View

11.

Holgado M, Anguiano-Dominguez A, Martin-Banderas L . Contact lenses as drug-delivery systems: a promising therapeutic tool. Arch Soc Esp Oftalmol (Engl Ed). 2019; 95(1):24-33. DOI: 10.1016/j.oftal.2019.07.009. View

12.

Yu Y, Feng R, Li J, Wang Y, Song Y, Tan G . A hybrid genipin-crosslinked dual-sensitive hydrogel/nanostructured lipid carrier ocular drug delivery platform. Asian J Pharm Sci. 2020; 14(4):423-434. PMC: 7032125. DOI: 10.1016/j.ajps.2018.08.002. View

13.

Garcia-Millan E, Quintans-Carballo M, Otero-Espinar F . Improved release of triamcinolone acetonide from medicated soft contact lenses loaded with drug nanosuspensions. Int J Pharm. 2017; 525(1):226-236. DOI: 10.1016/j.ijpharm.2017.03.082. View

14.

Dong Y, Dong P, Huang D, Mei L, Xia Y, Wang Z . Fabrication and characterization of silk fibroin-coated liposomes for ocular drug delivery. Eur J Pharm Biopharm. 2015; 91:82-90. DOI: 10.1016/j.ejpb.2015.01.018. View

15.

Patel A, Cholkar K, Agrahari V, Mitra A . Ocular drug delivery systems: An overview. World J Pharmacol. 2015; 2(2):47-64. PMC: 4289909. DOI: 10.5497/wjp.v2.i2.47. View

16.

Law S, Huang K, Chiang C . Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. J Control Release. 2000; 63(1-2):135-40. DOI: 10.1016/s0168-3659(99)00192-3. View

17.

Sharma A, Tandon A, Tovey J, Gupta R, Robertson J, Fortune J . Polyethylenimine-conjugated gold nanoparticles: Gene transfer potential and low toxicity in the cornea. Nanomedicine. 2011; 7(4):505-13. PMC: 3094737. DOI: 10.1016/j.nano.2011.01.006. View

18.

Li Q, Li Z, Zeng W, Ge S, Lu H, Wu C . Proniosome-derived niosomes for tacrolimus topical ocular delivery: in vitro cornea permeation, ocular irritation, and in vivo anti-allograft rejection. Eur J Pharm Sci. 2014; 62:115-23. DOI: 10.1016/j.ejps.2014.05.020. View

19.

Xiong S, Gao H, Qin L, Jia Y, Ren L . Engineering topography: Effects on corneal cell behavior and integration into corneal tissue engineering. Bioact Mater. 2019; 4:293-302. PMC: 6829100. DOI: 10.1016/j.bioactmat.2019.10.001. View

20.

ElMeshad A, Mohsen A . Enhanced corneal permeation and antimycotic activity of itraconazole against Candida albicans via a novel nanosystem vesicle. Drug Deliv. 2014; 23(7):2115-2123. DOI: 10.3109/10717544.2014.942811. View